Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2004 4
2005 2
2006 10
2007 21
2008 16
2009 14
2010 11
2011 17
2012 19
2013 20
2014 20
2015 15
2016 13
2017 11
2018 13
2019 7
2020 8
2021 7
2022 8
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Results by year

Filters applied: . Clear all
Page 1
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Shore ND, et al. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study.
Huang HP, Chen CH, Chang KH, Lee MS, Lee CF, Chao YH, Lu SY, Wu TF, Liang ST, Lin CY, Lin YC, Liu SP, Lu YC, Shun CT, Huang WJ, Lin TP, Ku MH, Chung HJ, Chang YH, Liao CH, Yu CC, Chung SD, Tsai YC, Wu CC, Chen KC, Ho CH, Hsiao PW, Pu YS. Huang HP, et al. Among authors: pu ys. J Transl Med. 2023 Oct 11;21(1):714. doi: 10.1186/s12967-023-04424-9. J Transl Med. 2023. PMID: 37821919 Free PMC article.
LMNB1, a potential marker for early prostate cancer progression.
Hong JH, Liang ST, Wang AS, Yeh CM, Huang HP, Sun CD, Zhang ZH, Lu SY, Chao YH, Chen CH, Pu YS. Hong JH, et al. Among authors: pu ys. Am J Cancer Res. 2022 Jul 15;12(7):3390-3404. eCollection 2022. Am J Cancer Res. 2022. PMID: 35968338 Free PMC article.
Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
Chiong E, Murphy DG, Akaza H, Buchan NC, Chung BH, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Ng CF, Ong T, Pu YS, Saad M, Schubach K, Türkeri L, Umbas R, Le Chuyen V, Williams S, Ye DW; ANZUP Cancer Trials Group; Davis ID. Chiong E, et al. Among authors: pu ys. BJU Int. 2019 Jan;123(1):22-34. doi: 10.1111/bju.14489. Epub 2018 Aug 19. BJU Int. 2019. PMID: 30019467 Review.
Pneumopelvis, pneumoureter and pneumobladder.
Weng WC, Pu YS, Yu HJ, Huang CY. Weng WC, et al. Among authors: pu ys. QJM. 2012 Feb;105(2):199-200. doi: 10.1093/qjmed/hcq245. Epub 2011 Jan 7. QJM. 2012. PMID: 21217115 No abstract available.
210 results